Statins and Adverse Cardiovascular Events in Moderate-Risk Females: A Statistical and Legal Analysis with Implications for FDA Preemption Claims
- 1 September 2008
- journal article
- research article
- Published by Wiley in Journal of Empirical Legal Studies
- Vol. 5 (3) , 507-550
- https://doi.org/10.1111/j.1740-1461.2008.00132.x
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- A population-based analysis of statin utilization in British ColumbiaClinical Therapeutics, 2007
- Decisions by regulatory agencies: are they evidence-based?Trials, 2007
- Random-effects model for meta-analysis of clinical trials: An updateContemporary Clinical Trials, 2007
- A comparison of heterogeneity variance estimators in combining results of studiesStatistics in Medicine, 2006
- Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 DiabetesDiabetes Care, 2006
- Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trialsBMJ, 2006
- Low-dose atorvastatin in severe chronic kidney disease patients: A randomized, controlled endpoint studyScandinavian Journal of Urology and Nephrology, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 UpdateCirculation, 2002
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002